The incidence of acute kidney injury (AKI) in critically ill pediatric patients has been reported as increasing to 25 %, depending on population characteristics. The etiology of AKI has changed over the last 10-20 years from primary renal disease to the renal conditions associated with systemic illness. The AKI in pediatric population is associated with increased mortality and morbidity, and preven tion is needed to reduce the consequence of AKI. It is known that the most important risk factors for AKI in critically ill pediatric patients are clinical conditions to be associated with decreased renal blood flow, direct renal injury, and illness severity. Renal hypoperfusion leads to neurohormonal activation including renin-angiotensinaldosterone system, sympathetic nervous system, antidiuretic hormone, and prostaglandins. Prolonged renal hypoperfusion can result in acute tubular necrosis. The direct renal injury can be predisposed under the condition of renal hypoperfusion, and appropriate treatment of volume depletion is important to prevent AKI. The preventable causes of AKI include contrast-induced nephro pathy, hemodynamic instability, inappropriate mediation use, and multiple nephrotoxic insults. Given the evidence of preventable factors for AKI, several actions such as the use of protocol for prevention of contrast-induced nephropathy, appropriate treatment of volume depletion, vigorous treatment of sepsis, avoidance of combinations of nephrotoxic medications, and monitoring of levels of drugs should be recommended.
Introduction
The definitions and characterization of acute kidney injury (AKI) in children have advanced significantly over the past 2 decades. Acute kidney injury is common in critically ill children and is associated with increased morbidity and mortality 1) . Acute kidney injury in association with sepsis, multiple organ involvement, and fluid overload carries heightened risk 1) . Gene probes and urinary biomarkers represent intriguing tools for predicting and moni toring pediatric AKI.
To prevent AKI, the stepbystep approach such as coronary angina is needed. First step is risk factor and symptom assessment 1) . Risk factor for coronary angina such as smoking or hypercholesterolemia has been known and the patients usually manifest the typical symptom such as chest pain. However, AKI dose not hurt. It means that there is no typical symptom in www.chikd.org AKI. In AKI, the risk factor evaluation is more important. Second step is to measure biomarker such as troponin I and assess AKI 1) . In the past, serum creatinine (Cr) has been used as a biomarker of AKI. It has been known that even as small elevation of serum Cr may reflect significant kidney damage and be associated with poor outcome 1) . It means that serum Cr is a late marker of AKI. The numerous biomar kers have been addressed as an early marker of AKI. Third step is intervention such as thrombolysis in coronary angina. It is difficult to prevent AKI because AKI does not show typical symptoms and there was little data for the earlier biomarker of AKI. In the past decade, research has been expanded to discover risk factor, biomarkers and intervention in AKI. In the literature, the etiology, risk fac tors, assessment modalities, and prevention in pediatric AKI patients will be addressed.
Etiology of AKI
The etiology of AKI has changed over the last 1020 years from primary renal disease (hemolytic uremic syndrome, glomerulonephritis) to the renal complications of systemic illness or associated treatment (sepsis, cardiac disease, oncolo gic disease). Common causes of AKI in critically ill pediatric patients were renal ischemia, nephrotoxic medi cation and sepsis, and these conditions lead to acute tubular necrosis. The etiology of AKI is classified to prerenal, renal (intrinsic), or postrenal disease (Table 1) . Causes of pre renal azotemia are absolute loss of effective blood volume such as hemorrhage and relative loss due to capillary leak in sepsis. Extracorporeal membrane oxygenation and heart failure can be prerenal causes. Pharmacologic agents such as indomethacin, tolazoline, angiotensinconverting enzyme inhibitor, and angiotensin receptor blockers can cause AKI by decreasing renal perfusion. When renal blood flow decreases, renal autoregulation preserves glomerular filtration rate (GFR) by increasing renal sympathetic tone, activation of the reninangiotensinaldosterone system, and increased activation of hormones such as vasopressin and endothelin. If tubular function is intact, sodium and urinary urea reabsorption can increase in response to decreased renal blood flow. These renal hemodynamic changes maintain systemic volume expansion and blood pressure. This situation is reflected by low urine sodium concentrations, low urine urea concentration and increased blood urea to creatinine ratio. This period of renal hypoper fusion, so called "renal angina" is critical to recognize and In contrast to prerenal AKI, renal function abnorma lities in intrinsic AKI have been supposed not to be immedia tely reversible. The severity of intrinsic AKI ranges from mild tubular dysfunction to acute tubular necrosis and corticomedullary necrosis with irreversible renal damage. The intrinsic kidney injury can be divided into glomerular, vascular, tubular, and interstitial disease. Glomerulone phritis/vascular diseases should be suspected when children present with AKI without an identifiable cause. The exami nation of the urine sediment can differentiate glomerular from tubular injury, and the laboratory evaluation for autoimmune antibodies and a diagnostic kidney biopsy may be helpful to differentiate the cause. Pharmacologic agents are one of the most common causes of nephrotoxic AKI, and these toxins can cause AKI by decreasing renal perfusion (nonsteroidal antiinflammatory drug, diure tics, angiotensinconvertingenzyme inhibitor), by direct tubular injury (aminglycocides, cephalosporins, ampho tericin B, rifampin, vancomycin, nonsteroidal antiinfla mmatory drug, contrast media, myoglobin/hemoglobin), by interstitial nephritis, or tubular obstruction (acyclovir, uric acid).
The common causes of postrenal AKI are congenital malfor mations including imperforate prepuce, urethral stricture, prunebelly syndrome, and posterior urethral valves.
Other causes of acute obstruction include neurogenic bladder, extrinsic compression, and intrinsic obstruction from renal calculi or fungal balls. Depending on the cause and associated damage to the kidneys, the relief of the obstruction is essential to restore renal function.
In pediatric AKI series, the incidence of sepsis associated AKI has ranged from 9% to 34%, and sepsis associated AKI is also associated with lower survival.
The pathogenic mechanism of AKI in sepsis is complex and multifactorial, and has been known to be related to combination of blood f low alterations and cytokine mediated injury.
The "peak concentration hypothesis" has been proposed that the elevations and imbalances of both proinflamma tory and antiinflammatory mediators coupled with endo thelial dysfunction and altered coagulation cascade can synergistically induce AKI.
AKI frequently occurs with other organ failure in criti cally ill children. The complex pathophysiologic interac tion of heart and kidney dysfunction is described as cardio renal syndrome. Type 1 cardiorenal syndrome is primarily caused by acute cardiac disease with secondary acute renal impact, and common in the perioperative setting with acute decompensated heart failure. The interaction of liver and kidney known as hepatorenal syndrome is well reco gnized, but the pathophysiologic mechanisms remain unknown. AKI can occur in undergoing surgery for con genital heart disease, and the mechanisms are multifac torial. The ischemia results in ATP depletion and tubular cell death. The contact of RBC with the bypass circuit during cardiopulmonary bypass causes hemolysis, and in the presence of free radicals, the free iron participates in oxygen radical reactions. Loss of brush borders and disrup tion of cell polarity and cytoskeleton extend to apoptosis, and the desquamation of tubule cells into the lumen leads to the cast obstruction.
Risk factor assessment
In critically ill adult patients, multiple risk factors for AKI such as old age, diabetes, liver cirrhosis, congestive heart failure, chronic kidney disease, or cardiopulmonary bypass have been identified 1) . However, children typically do not have the comorbid conditions noted for adult patients 1) . There is a little data to evaluate the risk factor for AKI in children. Bailey D et al. reported the risk factors of AKI in critically ill children in a singlecenter, prospective obser vational study over 1 year 2) . The enrolled patients were the pediatric intensive care unit population with 3 days to 18 years of age 2) . Acute kidney injury was defined as doubling of baseline serum creatinine 2) . In chronic kidney disease patients, AKI was defined as 25% increase in serum Cr 2) .
The incidence rate of AKI was 4.5% 2) . Significant risk factors for AKI were thrombocytopenia, age > 12 years, hypoxemia, hypotension, and coagulopathy 2) . A few studies for risk factors for developing AKI in children were per formed and the risk factors included invasive mechanical ventilation, vasoactive medications, nephrotoxic medica tions, sepsis, multiple organ failure, volume depletion, thrombocytopenia, hypoxemia, neurologic dysfunction, and stem cell transplantation 1) . It is recommended that all children with any of these risk factors should be monitored for the development of AKI.
Acute kidney injury assessment 1. Definition of Acute kidney injury
It has been known that children with small changes in serum Cr or with high degree of fluid overload are at risk for poor outcomes 1) . The widely used AKI criteria in children were based on the change of serum Cr, and AKI can be assessed by criteria. In 2004, the Acute Dialysis Quality Initiative group developed the first consensus multidimensional AKI definition, termed the RIFLE criteria. In 2007, AckanArikan developed and validated a pediatric modified version of the RIFLE criteria (pRIFLE) in critically ill children (Table 2) 3)
. RIFLE has 3 AKI staging strata, Risk, Injury, Failure, and 2 outcome criteria, Loss and EndStage Kidney Disease 3) . AKI develo pment by RIFLE (RIFLER) is defined as a 50% rise in serum Cr (or 25% decrease in estimated Cr clearance) over baseline or by urine output of less than 0.5 mL/kg/hour for 6 hours 3) . RIFLEI and RIFLEF are each defined by greater changes in Cr or urine output 3) . And the RIFLE was modified by the Acute Kidney Injury Network (AKIN) in 2007 to include a 0.3 mg/dL serum Cr rise in less than 48 hours for the AKI defi nition 4) . In 2012, an international guideline was dev eloped by the Kidney Disease Improving Global Outcomes (KDIGO) ( Table 3) 5) . Acute Kidney Injury Work Group harmonized RIFLE, AKIN, and pRIFLE into a single standardized definition 5) . The KDIGO AKI definition and staging criteria should be used at the current time unless further modifications are warranted by prospective study.
Fluid overload
Acute kidney injury can be assessed by fluid overload. Decreased renal function and oliguria in AKI result in fluid overload 1, 6) . However, fluid overload itself may con tri bute to AKI 1, 6) . In patients with AKI, outcomes progressively worsened with increasing degree of fluid overload 1, 6) . Fluid balance was an independent risk factor for mortality, and the early institution of renal replacement therapy was asso ciated with better outcome 1, 6) . Therefore, the aggressive use of diuretics and early initiation of hemofiltration is suggested. Goldstein SL et al. reported that lesser percent fluid overload at continuous venoveno hemofiltration (CVVH) initiation was associated with improved outcome when sample was adjusted for severity of illness 6) . Foland et al. reported that percent fluid overload was significantly lower in survivors compared with nonsurvivors in children with multiple organ dysfunction syndrome and percent fluid overload was independently associated with survival when severity of illness is adjusted 7) . Gillespie R et al.
reported that pediatric continuous renal replacement therapy (CRRT) survival outcomes progressively worsened with increasing percent fluid overload and children with high fluid overload (>10%) at CVVH initiation were at 3 times greater risk of mortality 8) .
Biomarker
Acute kidney injury can be assessed by biomarker, but serum Cr has a few limitations. Because, serum Cr is a late functional marker of AKI, serum Cr may not change until loss of 2550% kidney function 1, 9, 10) . It may take days after an injury before a rise in serum Cr. At lower glomerular filtra tion rate, serum Cr will overestimate renal function 1, 9, 10) . Serum Cr varies by muscle mass, hydration status, sex, age, and method of measurement 1, 9, 10) . Novel biomarker to detect development and severity of kidney injury earlier than serum Cr in AKI is needed and the utilities of biomarkers are as follow 9) ; (1) Early diagnosis, (2) Define severity of injury, monitor AKI course, (3) Define AKI subtypes & etiology (prerenal, septic, nephrotoxic), (4) Monitor response to AKI interventions, (5) Risk stratify for poor outcomes (dialysis need, CKD, mortality), (6) Identify location of renal tubular injury. The ideal qualities of a biomarker are as follow 10) ; (1) Accurate, reliable, (2) Relatively noninvasive/acceptable to patients, (3) Rapidly measurable, standardized assay, (4) Sensitive/specific with reproducible cutoff values. Urine neutrophil gelatinaseassociated lipocalin (NGAL), kidney injury molecule 1 (KIM1), interleukin 18 (IL18), interleukin 6 (IL6), interleukin 8 (IL8), β2micro glo bulin, CystatinC, and Livertype fatty acidbinding protein (LFABP) are urinary and serum biomarkers for the diagnosis of AKI in pediatric patients (Table 4) 1119) .
NGAL is expressed in proximal and distal nephron and binds and transports ironcarrying molecules 10, 11) . NGAL plays an important role in injury and repair and rises very early (hours) after injury in animals, confirmed in children with cardiopulmonary bypass, critically ill children, and children with contrastinduced nephropathy 1113) . In a pro spective cohort study of critically ill children, mean and peak urine NGAL concentrations increased with worsening pRIFLE status, and urine NGAL concentrations rose in AKI, 2 days before and after a 50% or greater rise in serum creatinine, without change in control urine NGAL 12) . This study suggested that urine NGAL might be a useful early AKI marker that predicted development of severe AKI in a heterogeneous group of patients with unknown timing of kidney injury. IL18 plays a role in inflammation, activat ing macrophages and mediates ischemic renal injury 13) . IL 18 antiserum to animals protects against ischemic AKI 10) . Urinary IL18 was reported to be an AKI biomarker in critically ill children, children with portcardiac surgery, 15) 2011
Cystatin-C S Post-cardiac surgery Krawczeski et al. 18) 2010 LFABP U Post-cardiac surgery Portilla et al. 19) 2008 NGAL, neutrophil gelatinase-associated lipocalin; S, serum; U, urine; CIN, contrast-induced nephropathy; IL-18, interleukein-18; IL-6, interleukin-6; IL-8, interleukin-8; KIM-1, kidney injury molecule-1; β2-MG, β2-microglobulin; LFABP, Liver-type fatty acid-binding protein.
and pediatric patients in emergency department 1315) .
Washburn K et al. reported that urine IL18 might be used as a useful early AKI marker in critically ill children 14) .
Urinary IL6 and serum IL8 was confirmed in children with portcardiac surgery 16, 17) . KIM1 is an epithelial trans membrane protein, and is involved in cellcell interaction 10) . KIM1 appears to have strong relationship with severity of renal injury 10) . Du Y et al. reported that KIM1 and β2 microglobulin could be used as urinary biomarkers to detect AKI in pediatric emergency center 15) . Serum cystatin C and urinary LFABP was reported as a biomarker of AKI after pediatric cardiac surgery [18, 19] . In the pediatric setting, many studies were conducted postcardiac surgery, and the collaborations among pediatric nephrology, cardio logy, emergency medicine, and critical care medicine are needed for the research of AKI biomarkers.
Therapeutic intervention
In the timecourse of AKI, initiation of AKI can involve hemodynamic changes in glomerular filtration rate, sub clinical tubular injury or both processes occurring simulta neously. A short time window may exist where specific therapy might reverse AKI. Established AKI requires days to weeks for recovery, and during this period supportive therapy and the avoidance of secondary renal injury is very important. Secondary injury may result in nonrecovery of renal function or chronic kidney disease and endstage renal disease.
Intervention of AKI is composed of diagnostic evalua tion to uncover the underlying etiology, optimization of hemodynamics, minimize exposure to nephrotoxic medica tions, conservative fluid management after an initial resus cita tion, and maximize nutrition.
Fluid management
Attention to the patient's volume status is essential throug hout the hospital stay. Intake and output measurement does not take into account insensible losses. Therefore, obtaining daily weight measurement on the same scale is very important and, in combination with vital signs, heart rate, and blood pressure, it will give the clinician a better sense of the patient's volume status.
Avoidance of further renal injury
1) Drug dosing in AKI Toxicity of drugs can be avoided by careful monitoring and adjusting the dose in accordance with the patient's chan ging renal function status. Antibiotics such as amino glycosides or vancomycin can be used safely in patients with AKI with careful attention to serum drug levels. Antibacterials usually need a high peak and lower trough level, and have to be given with longer dosing intervals 20) . Antiviral such as acyclovir might induce crystal nephro pathy and acute tubular necrosis, and adequate hydration is necessary to prevent renal injury. Amphotericin B can cause renal vasoconstriction associated AKI and toxic effect to distal tubular epithelium. To prevent these adverse effects, sodium and volume loading prior to administra tion of amphotericinB is needed. In the use of oral vori conazole, dosage adjustment in AKI is not necessary. Histamine antagonist can induce thrombocytopenia in AKI and dosage adjustment is needed. Proton pump inhibitor can be given with no dosage adjustment in AKI patients. Sucralfate is supposed to have a risk of aluminum accumulation in AKI. Phenytoin and levetiracetam can be used with dosage adjustment in AKI.
2) Contrastinduced nephropathy Contrastinduced nephropathy has been known to be the third most common cause of hospitalacquired AKI in adults. The pathophysiology has been supposed to be renal vasoconstriction through endothepin1 or inhibition of nitric oxide and toxic effect to the renal tubular epithelium 11) . Prevention include the fluid volume loading with sodium bicarbonate, avoiding nephrotoxic drug prior to contrast, the use of lower osmolarit y contrast agent, and Nacetylcystein 11) .
Specific intervention 1) Diuretics
Diuretics can be used to augment urine output but will not enhance solute clearance. Accordingly, increased urine output does not correlate with improvement of renal func tion or with improvement of solute clearance. Comparison of loop diuretics given as an intermittent bolus or by con tinuous infusion shows that the use of continuous infusion involves less exposure to these potentially toxic agents with the same amount of urine output 21) . Thiazidelike diuretics (e.g., oral metolazone or intravenous chloro th iazide) can be given to enhance the effectiveness of loop diuretics.
2) Potential therapies
There is no evidence to support the use of renal dose dopamine. However, fenoldopam, a selective dopaminergic1 Rc agonist has been reported to reduce the risk of AKI in critically ill adults and improve urine output in critically ill neonates following cardiopulmonary bypass 22) . Nacetyl cystein has been known to be effective in the prevention of contrastinduced nephropathy, but there is no evidence for prevention of AKI in critically ill patients 23) . It has been reported that human natriuretic peptide nesiritide might be favorable for renal hemodynamic effects and increase urine output after cardiac surgery 24) . Additionally, growth factor, erythropoietin, or freeradical scavengers have been tried as a potential therapy in AKI 2527) .
Nutrition
Nutrition is important in patients with AKI as part of ongoing care. Specialized formulas to maximize nutrition and minimize both solute and fluid excess can be delivered to patients with AKI 28, 29) . Enteral nutrition has an advan tage over parenteral nutrition and these formulas can be given either orally or by feeding tube to provide adequate caloric intake 28, 29) . These formulas deliver 2 cal/mL, with either no or low electrolytes (specifically, potassium and phosphorus) 28, 29) .
Conclusion
The AKI in pediatric population is associated with increased mortality and morbidity, and prevention is needed to reduce the consequence of AKI. To prevent AKI, the close monitoring of the pediatric patients with risk factor and the AKI assessment by AKI definition, fluid overload, and biomarker are necessary. Intervention should include the use of protocol for prevention of contrastinduced nephropathy, appropriate treatment of volume depletion, vigorous treatment of sepsis, avoidance of combinations of nephrotoxic medications, and monitoring of levels of drugs. Critically ill children tend to be medically complex patients with multiple organ dysfunction, and the comprehensive team approach for early recognition of AKI and appro priate interventions are necessary to promote renal recovery and overall survival. The collaborative research should be conducted to find more accurate diagnostic methods such as biomarkers to detect AKI in pediatric patients under the complex situations such as intensive care unit, emer gency department, preterm birth, postcardiac surgery, and trauma.
